期刊文献+

美沙酮维持治疗门诊受治人群HCV感染及影响因素分析 被引量:2

Analysis of influencing factors of HCV infection in drug users from methadone maintenance therapy clinic in Xi'an
原文传递
导出
摘要 目的:了解西安市美沙酮维持治疗门诊受治人群丙型肝炎病毒(HCV)感染现状及其特点,为制订相应的干预措施提供科学依据。方法:对西安市美沙酮维持治疗门诊(MMT)2007年5月1日至2008年5月31日入组的404名海洛因依赖者进行问卷调查,并采静脉血检测抗-HCV抗体。结果:404名吸毒者中,抗-HCV阳性率为60.6%。静脉注射史中,曾静脉注射吸毒者280人,抗-HCV阳性率为75.4%,高于非静脉吸毒者的27.4%,差异有统计学意义(P<0.01)。有14人曾共用注射器具,占3.5%(14/404)。共用注射器具的感染率为78.6%。未共用注射器具者的HCV感染率为60.0%。多性伴者HCV感染率明显高于单一性伴或无性伴者,P<0.01,有统计学意义。结论:西安市海洛因依赖人群HCV感染率高,相关危险行为普遍存在。 Objective: To describe the characteristics of HCV infection among drug users of xian, and provide baseline data for valid intervention. Methods: Face-to-face interview with detailed questionnaire was conducted amongst 404 drug users in the methadone maintenance therapy (MMT) clinic of Xian,and blood sample was collected and tested for HCV antibody. Results: The overall anti-HCV antibody-positive rate was 60.6%,while the rate was75.4 % among 280 IDUs, significantly higher than that of NIDUs (27.4%, Х^2=10.26,P〈0.01). 3.5% (14/404) had shared syringes and needles with other IDUSo A significantly higher HCV infection rate was found among drug users who have more than 1 sex partner, compared with those who have single or no sex partner. Conclusion: High HCV infection rate was observed among drug users in MMT clinic of Xiani,and behaviors at high risk were commonly identified.
出处 《中国药物滥用防治杂志》 CAS 2009年第4期207-209,共3页 Chinese Journal of Drug Abuse Prevention and Treatment
关键词 美沙酮维持治疗 静脉注射吸毒 丙型肝炎病毒 Methadone maintenance therapy Drug abuse Intravenous drug abuse HCV
  • 相关文献

参考文献3

二级参考文献26

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献749

同被引文献5

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部